Viracta Therapeutics Inc (NASDAQ:VIRX)
| 1.42 Delayed Data As of 3:59pm ET |  +0.09 / +6.77%Today’s Change | 0.88 Today|||52-Week Range 5.75 | -2.74% Year-to-Date |
Latest VIRX News | Press Releases
| Insider Sell: CFO and COO Daniel Chevallard Sells 3,635 Shares of Viracta Therapeutics Inc (VIRX) May 28 / GuruFocus News - Paid Partner Content | Insider Sell: CFO and COO Daniel Chevallard Sells 3,635 Shares of Viracta Therapeutics Inc (VIRX) May 27 / GuruFocus News - Paid Partner Content |
Today’s Trading
| Previous close | 1.33 |
| Today’s open | 1.35 |
| Day’s range | 1.32 - 1.43 |
| Volume | 4,478 |
| Average volume (3 months) | 166,199 |
| Market cap | $56.1M |
Data as of 3:59pm ET, 06/01/2023
Growth & Valuation
| Earnings growth (last year) | +63.85% |
| Earnings growth (this year) | +10.00% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 1.01 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| MEIPMEI Pharma Inc | -0.20 | -2.60% |
| ASMBAssembly Biosciences... | +0.00 | +0.44% |
| MBIOMustang Bio Inc | -0.22 | -3.44% |
| EIGREiger BioPharmaceuti... | 0.00 | 0.00% |
Data as of 3:59pm ET, 06/01/2023
Financials
| Next reporting date | August 9, 2023 |
| EPS forecast (this quarter) | -$0.29 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$49.2M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cardiff, California |
Forecasts
